Susquehanna analyst James Friedman maintains EPAM Sys (NYSE:EPAM) with a Positive and lowers the price target from $496 to $475.
Expert Ratings for Repligen
Analysts have provided the following ratings for Repligen (NASDAQ:RGEN) within the last quarter: